知镜 Cognispect · 医学文献与研究工作台

The deubiquitinase YOD1 in renal tubular epithelial cells promotes diabetic kidney disease by stabilizing KEAP1.

Zhao QQ, Zhao Y, Fan SJ, Jiang YC, Zheng TH, Bao SJ, Xu DY, Zheng ZZ, Jin YH, Wang Y, Chong SY, Liang G, Zhu H.
Acta pharmacologica Sinica · 2026-09-14 · PMID 42736454

文献摘要

Renal tubular epithelial cell (RTEC) injury is an early event in diabetic kidney disease (DKD) and is a key driver of its development and progression. Deubiquitinating enzymes (DUBs) play crucial roles in the progression of diseases by regulating the stability of substrate proteins. This study aims to elucidate the regulatory role and underlying mechanisms of the deubiquitinating enzyme ovarian tumor domain-containing 2 (YOD1) in RTEC injury and DKD. Through transcriptomics and single-cell mRNA sequencing, we confirmed that YOD1 expression is upregulated in diabetic kidneys and that YOD1 is predominantly localized in RTECs. RTEC-specific Yod1 knockout alleviates renal injury in diabetic mice. RNA-seq analysis revealed a positive correlation between YOD1 and the oxidative stress signaling pathway. Interactome analysis revealed the oxidative stress regulatory protein Kelch-like ECH-associated protein 1 (KEAP1) as a YOD1 substrate. YOD1 deubiquitinates and stabilizes KEAP1, which suppresses NRF2 nuclear translocation under high glucose and palmitic acid (HG/PA) stimulation, thus increasing oxidative stress. Similarly, the ROS scavenger N-acetylcysteine (NAC) can alleviate oxidative stress injury to some extent by reducing ROS levels in RTECs. Finally, we confirmed that the YOD1 pharmacological inhibitor G5 has therapeutic effects on kidney injury in diabetic mice. Our findings demonstrate that the YOD1-KEAP1 axis mediates oxidative stress injury in RTECs and highlight that targeting YOD1 represents a potential treatment approach for DKD.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。